about
P366
Advances and challenges in malaria vaccine developmentImmune mechanisms in malaria: new insights in vaccine developmentDevelopment of a metabolically active, non-replicating sporozoite vaccine to prevent Plasmodium falciparum malariaEuropean Vaccine Initiative: lessons from developing malaria vaccinesVaccines: from empirical development to rational designDevelopment and characterization of synthetic glucopyranosyl lipid adjuvant system as a vaccine adjuvantPreclinical and clinical development of plant-made virus-like particle vaccine against avian H5N1 influenzaThe end of the line for hookworm? An update on vaccine developmentImmunogenicity and efficacy of oral vaccines in developing countries: lessons from a live cholera vaccineUse of formative research in developing a knowledge translation approach to rotavirus vaccine introduction in developing countriesCost-effectiveness of introducing a rotavirus vaccine in developing countries: the case of MexicoVaxjo: a web-based vaccine adjuvant database and its application for analysis of vaccine adjuvants and their uses in vaccine developmentA new insight into hepatitis C vaccine developmentVaxign: the first web-based vaccine design program for reverse vaccinology and applications for vaccine developmentWhen good vaccines go wild: Feral Orthopoxvirus in developing countries and beyondGlycan masking of Plasmodium vivax Duffy Binding Protein for probing protein binding function and vaccine developmentKey steps in developing a cognitive vaccine against traumatic flashbacks: visuospatial Tetris versus verbal Pub QuizThe use of nonhuman primate models in HIV vaccine developmentDevelopment of a new vaccine for the prevention of Lassa fever.Current status of syphilis vaccine development: need, challenges, prospectsRecent advances in Ebolavirus vaccine developmentProduct Development Partnerships Hit Their Stride: Lessons From Developing A Meningitis Vaccine For AfricaZika highlights need for ethical framework for developing vaccines for pregnant womenEstablishing a Global Vaccine-Development FundZika as still another argument for a new path to vaccine developmentPregnancy in the Time of Zika: Addressing Barriers for Developing Vaccines and Other Measures for Pregnant WomenDevelopment of AAVLP(HPV16/31L2) particles as broadly protective HPV vaccine candidateKissing-loop interaction between 5' and 3' ends of tick-borne Langat virus genome 'bridges the gap' between mosquito- and tick-borne flaviviruses in mechanisms of viral RNA cyclization: applications for virus attenuation and vaccine developmentDevelopment of a Zika vaccineHost background immunity and human immunodeficiency virus protective vaccines, a major consideration for vaccine efficacy in Africa and in developing countries.Molecular host-pathogen interaction in brucellosis: current understanding and future approaches to vaccine development for mice and humansPerformance of rotavirus vaccines in developed and developing countriesNovel vaccine development strategies for inducing mucosal immunityMeasles-mumps-rubella vaccine and the development of autism or inflammatory bowel disease: the controversy should endThe development of a stable smallpox vaccineTrends affecting the future of vaccine development and delivery: the role of demographics, regulatory science, the anti-vaccine movement, and vaccinomicsThe failed HIV Merck vaccine study: a step back or a launching point for future vaccine development?A single-dose influenza A (H5N1) vaccine safe and immunogenic in adult and elderly patients: an approach to pandemic vaccine developmentConsiderations for the development of Zika virus vaccinesNew vaccines to boost child care in developing countries
P921
Q21032463-5E7510F1-A78F-4A8F-A26D-13C947BF221BQ21032484-E13323FC-40EC-47CC-A08E-B2DDE0446BD4Q21032534-65D7B337-ED76-402E-85F3-E1454352C410Q21032652-DC6EE10D-36E9-4B9B-9BBD-689D752D2EF5Q21089599-5512B5E3-4E32-4923-ADFC-EAC230432D4DQ21091066-F724542C-DEC9-4F6A-92D6-81D94E09FCF0Q21091074-10F563F3-81D4-4871-A42F-D1E9AFB8AEAAQ21092392-49435D00-6DE2-4D41-94AE-2CECDCE869B4Q21245322-537F91AC-3CC9-4DCC-A920-7BAEAF14AA78Q21257223-B51BAB33-8A0A-4C3A-A051-423634197FEEQ21261530-75C26E61-E1BE-4017-A188-A63803FFDECCQ21284959-9C20249A-1EAE-4954-A349-D175C9ADA763Q21296858-AB11ACAE-B1D6-48E3-AAA1-A8F78162D6A9Q21328677-AEFBED42-ECF5-47E5-8F75-AB9DEF811A95Q21558354-29AED31C-612D-41D4-BFAB-FDA554334B10Q21558777-816CFD1F-E172-4512-B9BE-7211FE011922Q21562148-D311AA5D-876C-48A6-8227-024FDFF628E2Q21563403-7D937087-34C2-46D0-BF75-753DF243A380Q21563440-84ABD255-CBEE-4975-8498-40EFB2B946C2Q22251428-5C7F6A92-1852-4E3E-8E0E-D486CB57BF17Q22305433-03E58259-0793-47F8-942B-3583C1D1B346Q22306071-6E9EF9C9-8E3F-4C81-9D03-DDCC857C16E0Q23308159-0F9373D0-CFE9-47C7-BEB8-E416952615F8Q24083038-7B671771-5E76-4B63-AA5B-D0E3FDBA0874Q24083039-76CD8BAB-5BED-4084-A3E2-CFCBCFB480ADQ24247074-E5D93AAF-A203-4F82-B82C-5CC201B7AC89Q24288709-F9BBAB32-9676-4217-BCC6-65CD873D9425Q24289179-00960D07-F376-4994-9905-A7AC4E75A3AAQ24289675-615F9275-EA40-4851-B762-B3008D50BA05Q24531918-B82DCE79-912F-45BC-9540-A12A63AFB5B0Q24545524-5DB7FB35-BDC0-4F06-B0F9-CBB1B066559BQ24600612-C8F46F64-420B-431A-9879-D55968F6EF5FQ24607533-F0D7CD1E-084B-49C6-B1E6-D3FCF401E777Q24629774-5A1A8DEA-7CB0-4134-A793-E51413D1C10FQ24644342-11EC81B8-C055-4836-96F9-A4AC31547C5AQ24648874-0381D52E-651F-49F4-A25F-4A1370297E49Q24652185-F6CF6802-26F3-4C4C-A3C9-38469DECBD72Q24656615-D15D5EAF-1F33-4614-A6C1-2D5A314ABA91Q24657912-B4A65587-7D4B-4EA7-AB2C-1C5C398007FDQ24657940-0362E5C4-D2B3-4F26-946B-4060D1CCA053
P921
description
research field
@en
name
conception de vaccins
@fr
disvolvado de vakcino
@eo
vaccine development
@en
type
label
conception de vaccins
@fr
disvolvado de vakcino
@eo
vaccine development
@en
prefLabel
conception de vaccins
@fr
disvolvado de vakcino
@eo
vaccine development
@en